Compare MSLE & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSLE | NYXH |
|---|---|---|
| Founded | N/A | 2009 |
| Country | Canada | Belgium |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.6M | 161.9M |
| IPO Year | 2007 | 2021 |
| Metric | MSLE | NYXH |
|---|---|---|
| Price | $9.12 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 16.7K | ★ 185.9K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.44 | $1.26 |
| 52 Week High | $13.39 | $6.87 |
| Indicator | MSLE | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 58.75 |
| Support Level | $6.71 | $1.28 |
| Resistance Level | $9.75 | $1.70 |
| Average True Range (ATR) | 0.48 | 0.07 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 14.78 | 59.12 |
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.